REGN(Regeneron Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $16.07B | $12.17B | $13.12B | $14.20B | $14.34B |
| 毛利润 | — | — | — | — | — |
| 营业利润 | $8.95B | $4.74B | $4.05B | $3.99B | $3.58B |
| 净利润 | $8.08B | $4.34B | $3.95B | $4.41B | $4.50B |
| 经营现金流 | $7.08B | $5.01B | $4.59B | $4.42B | $4.98B |
| 自由现金流 | $6.53B | $4.42B | $3.88B | $3.66B | $4.08B |
| 摊薄每股收益 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |